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EFFECTS OF ALPHA-2 ADRENERGIC AGONISM ON EXCESSIVE ALCOHOL  




RATIONALE– Alcohol use disorder (AUD) is a devastating psychiatric disease that 
affects millions of people every year. Despite its prevalence, there is still a poor 
understanding of its neurobiological underpinnings, and effective treatment options are 
very limited. AUD is characterized by uncontrolled, heavy drinking and is also associated 
with the development of mechanical allodynia, a sensory abnormality which manifests as 
painful sensations following innocuous tactile stimuli. The adrenergic/noradrenergic 
system has been previously shown to play a role in modulating ethanol drinking behavior 
and withdrawal symptoms, and it has also been shown to play a key role in nociception. 
The α2-adrenoceptor, in particular, exerts an inhibitory effect on adrenergic and non-
adrenergic neurons. Even though this receptor system has been extensively studied its 
precise role in excessive ethanol drinking and in alcohol withdrawal-induced mechanical 
allodynia is still poorly understood. 
 
OBJECTIVES– The objectives of this study were to determine whether the α2-
adrenoceptor agonist, clonidine, reduces ethanol drinking behavior and withdrawal 




METHODS– C57Bl/6J  mice we subject to an intermittent, two-bottle choice paradigm 
with 24 hr access to a 20% (v/v) ethanol solution and water every other day (Mondays, 
Wednesdays, and Fridays) (MWF group). After stabilization of intake, mice were 
intraperitoneally administered with clonidine (0-160 µg/kg, i.p.) its effects on ethanol, 
water, and food intake were determined at different time points. In a second set of 
experiments, the effects of systemically administered clonidine on nociceptive threshold 
was determined following 72 hrs of alcohol abstinence as well as in control, ethanol-
naïve mice, using an electronic von Frey device. In a third set of experiments, the effects 
of clonidine were tested on 1.15% (w/v) sucrose intake, using a procedure identical to that 
used for ethanol drinking (intermittent, 2-bottle choice on Mondays, Wednesdays, and 
Fridays). Mice were then treated with clonidine and its actions on sucrose, water and food 
intake were determined. 
 
RESULTS– Systemic administration of clonidine markedly reduced ethanol intake and 
decreased mechanical allodynia following prolonged abstinence from alcohol. On the 
other hand, the treatment had no effect of the consumption of alternate reinforcers, such 
as sucrose. 
 
CONCLUSION– Our results indicate that α2-adrenoceptor agonism may be a viable 
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Alcohol Use Disorders 
Alcohol is one of the most abused substances in the United States and the most 
regularly consumed mind-altering substance across a multitude of cultures(Lim et al., 
2012). In 2010, the total economic cost of excessive drinking in the United States was 
249 billion dollars with almost 191 due to binge drinking only (Sacks et al., 2015).  
Repeated cycles of alcohol use can result in Alcohol Use Disorder (AUD), defined by the 
DSM-V as “a cluster of behavioral and physical symptoms which can include 
withdrawal, tolerance and craving” (American Psychiatric Association, 2013; Grant et al., 
2015). An estimated 13.1% of people in the United States suffer from AUD at some point 
in their life (Grant et al., 2015).  The transition from social use to alcohol addiction is 
attained by a combination of several factors ultimately resulting in a break of hedonic 
homeostasis and, in the attempt to maintain stability, in the development of a new 
neurochemical allostatic set point (Koob, 2003).  
The development of alcohol addiction can be thought of as a constantly worsening 
of a three stage cycle: intoxication, withdrawal-negative affect, and preoccupation-
anticipation (Koob and Le Moal, 1997). The intoxication stage is mainly chracterized by 
the activation of the mesolimbic pathway, which is responsible for the acute effects of 
alcohol (Volkow et al., 2003). Dopamine release within the nucleus accumbens (NAcc) 
facilitates an increased propensity for an individual to repeat the given behavior in the 
future (positive reinforcement), which is a key variable during the early stages of 
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addiction in promoting drug-seeking behavior (Koob and Le Moal, 1997). Withdrawal 
occurs following an abrupt cessation of drug administration and is accompanied by 
physical and emotional symptoms such as irritability, malaise, hyperactivity, sympathetic 
over-activation, loss of motivation toward rewards, and allodynia (McIntosh and Chick, 
2004; Egli et al., 2012; Koob and Volkow, 2016); these feelings of discomfort lead to 
compulsive alcohol use based on the avoidance of aversive stimuli (negative 
reinforcement) (Koob, 2003; Riley and King, 2009). Finally, the preoccupation-
anticipation stage is characterized by intense craving and drive to use drugs, resulting in 
relapse after a period of abstinence (Heinz et al., 2003; Koob and Volkow, 2016).   
As the cycle of addiction perpetuates, within-system and between-system 
neuroadaptations have been hypothesized to occur in response to chronic consumption of 
alcohol and periods of withdrawal (Koob and Bloom, 1988). Within-system mechanisms 
comprise of neuroadaptive changes occurring at the level of brain reward neurocircuitries 
involved in the initial positive reinforcing effects of alcohol; excessive alcohol 
consumption and, therefore, overstimulation of these neurocircuitries leads to their 
hyporesponsiveness and inability to properly process otherwise rewarding information. 
Within-system neuroadaptations have been best described in the mesocorticolimbic 
dopaminergic system, in which the resulting hypodopaminergic state is thought to 
contribute to the reduced sensitivity of the brain reward system and, therefore, to 
excessive alcohol intake (Koob and Bloom, 1988; Koob and Volkow, 2016). The 
between-systems mechanisms refer instead to the recruitment and/or dysregulation of 
neural systems which are typically not involved in the initial positive reinforcing effects 
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of alcohol, mainly stress neurotransmitters, such as corticotropin-releasing factor, 
dynorphin, and norepinephrine (Koob and Volkow, 2016).   
 
The Effect of Alcohol on Nociception 
Chronic alcohol use also dysregulates nociception which is the sensory nervous 
system’s response to harmful or potentially harmful stimuli. Alcohol has dose-dependent 
analgesic effects and is often used to self-medicate, as the amount of alcohol consumed 
by the general population has been associated with the frequency and severity of pain 
symptoms (Riley and King, 2009). However, as use of alcohol continues, tolerance to the 
analgesic effect develops (Gatch, 2009). Furthermore, chronic alcohol consumption can 
also cause alcoholic neuropathy, a primary axonal neuropathy characterized by axonal 
degeneration with reduced density of both small and large fibers (Mellion et al., 2011; 
Alongkronrusmee et al., 2016). Symptoms of neuropathic pain associated with chronic 
alcohol consumption are decreased superficial sensation, hyperalgesia, and weakness 
(Chopra and Tiwari, 2012; Maiya and Messing, 2014).A characteristic symptom of ALN 
is mechanical allodynia, defined as a painful sensation caused by innocuous tactile 
stimuli (Figure 1). Mechanical allodynia has roots in both peripheral and central neural 
pathways (Lolignier et al., 2015), and an association between alcohol withdrawal and the 
severity of mechanical sensitivity has been shown (Dina et al., 2006; Jochum et al., 2010; 
Alongkronrusmee et al., 2016). A 2006 study by Dina et al. found that an intermittent 
schedule of alcohol drinking that induces withdrawal (4 days on, 3 days off) resulted in 
increased pain sensitivity compared to rats under a continuous access schedule. 
 
4 
Interestingly, the number of times the animals were subjected to withdrawal was of 
greater importance to the development of allodynia than the total amount of alcohol 
consumed, suggesting that access intermittency is a key factor (Dina et al., 2006). It has 
been proposed that  individuals with AUD may in part continue to drink in the attempt to 
alleviate this elevated pain state that occurs during withdrawal (Dina et al., 2006; Egli et 






Figure 1: A schematic of pain sensitivity  
Graphical description of the change in the threshold of pain following an increasingly 
noxious stimuli. Pathological pain conditions shift the normal pain response curve (green 
dotted line) to the left, producing an enhanced pain response to normally noxious stimuli 




The Noradrenergic System 
Norepinephrine (NE) is released in the adrenal cortex as a circulating hormone, 
and also throughout the central nervous system where it acts as a neurotransmitter 
(Kovacs et al., 2002); The noradrenergic system innervates virtually the entire central 
nervous system and is responsible for maintaining wakefulness, as well as, modulating 
the collection and processing of sensory, memory, motor and attentional information 
(Berridge and Waterhouse, 2003). Consequently, this neurotransmitter system is 
implicated in disorders involving arousal, mood, reward, and pain (Koob, 2008; 
Fitzgerald, 2013; Taylor and Westlund, 2017). The majority of NE cell bodies in the 
brain originate in the locus coeruleus (LC) (Berridge and Waterhouse, 2003). These 
neurons project both to upstream central targets such as the medial prefrontal cortex 
(mPFC) and anterior cingulate cortex (ACC), as well as downstream spinal neurons 
modulating sensory information processing and regulating incoming peripheral 
information (Taylor and Westlund, 2017).   
NE binds to distinct receptor types a1, a2, and β adrenergic, which are located on 
both adrenergic and non-adrenergic cell types (Rohrer and Kobilka, 1998). While a1 
adrenoceptors are Gq-coupled and exert an excitatory action through protein kinase C 
(PKC) activation and release of intracellular Ca++, a2 adrenoceptors are predominately Gi-
coupled and inhibit adenylyl cyclase (Koob, 2008; Perez-Aso et al., 2013). The β 
adrenergic receptors are Gs-coupled and result in activation of neurons through 
stimulation of adenylyl cyclase (Chiamulera et al., 2010; Wu et al., 2014). NE shows 
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different binding affinities toward the different subtypes, with the a2 exhibiting the 
highest affinity and the β the lowest (Xing et al., 2016). 
The a2 adrenoceptors are of interest due to their ability to negatively modulate 
neurotransmitter levels by inhibiting release from synaptic terminals (Koob, 2008). a2A 
receptors, in particular, are predominantly presynaptic, but are also be found 
postsynaptically (Rohrer and Kobilka, 1998; Gyires et al., 2009). Presynaptic a2A 
adrenoceptors can be further classified into auto- or heteroreceptors (Starke, 2001). In 
both situations, a2 agonism results in a decrease of calcium influx into the presynaptic 
terminal and a subsequent decrease in vesicular fusion and neurotransmitter release 
(Gilsbach et al., 2009). However, while a2 autoreceptors are located on adrenergic 
neurons and facilitate negative feedback of NE, a2 heteroreceptors are found on non-
adrenergic neuron terminals and, therefore, inhibit the release of other neurotransmitters 
(Gilsbach et al., 2009). Postsynaptic a2A adrenoceptors primarily reside in the dorsal horn 
of the spinal cord and have been implicated in the antinociceptive effects of descending 
noradrenergic neurons (Sonohata et al., 2004; Gilsbach et al., 2009). In the central 
nervous system, they are found in the LC, hypothalamus, prefrontal cortex, cingulate 
cortex, striatum, olfactory bulb, basal ganglia, and hippocampus; however, it is unclear if 
these receptors are presynaptic or postsynaptic (Rosin et al., 1993; Aoki et al., 1994; 




Effects of Alcohol on the Noradrenergic System 
In the central nervous system, ethanol has important effects on both 
neurotransmitter release and receptor function within the NE system (Balldin et al., 1992; 
Tsai et al., 1995; Maldonado, 1997; De Witte et al., 2003). When administered acutely, 
alcohol exerts an inhibitory effect on NE neurons, resulting in a reduced firing rate and 
decreased NE levels in the brain (De Witte et al., 2003; West et al., 2015); this effect is 
thought to be due to alcohol-induced inhibition of presynaptic glutamate N-methyl-D-
aspartate receptors (NMDARs) which stimulate NE release (Tsai et al., 1995). During 
alcohol withdrawal, on the other hand, NMDARs are disinhibited, resulting in increased 
central excitation, which contributes to the sympathetic hyperactivation that is 
characteristic of withdrawal (Tokuyama et al., 2001; De Witte et al., 2003). Another 
contributor of the increased sympathetic activity is corticotropin releasing factor (CRF), 
whose release is increased during withdrawal (Ferrari et al., 2013; Pleil and Skelly, 
2018). CRF receptors are located on adrenergic neurons of the LC, promoting their firing 
and the release of NE (Linnoila et al., 1987; Valentino et al., 1993; Pleil and Skelly, 
2018). One direct consequence of this sympathetic disturbance is the large-scale 
activation of LC neurons and the subsequent release of NE (Tsai et al., 1995; Pleil and 
Skelly, 2018). Studies have shown that a2 sensitivity is reduced during the first stages of 
alcohol withdrawal, resulting in an inability to regulate NE release (Balldin et al., 1992; 
De Witte et al., 2003). It has also been shown that, during spontaneous abstinence of 
alcohol use, the availability of a2 adrenoceptors increases markedly, even though the 
hyposensitivity of the a2-adrenoceptors to NE remained, suggesting that the total number 
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of presynaptic a2 adrenoceptors may not necessarily correlate with functionality 
(Maldonado, 1997). 
 
The Noradrenergic System and Chronic Pain 
In non-pathological states, the LC is capable of interacting with other nociceptive 
areas, such as the DRt, ACC, mPFC, limbic system and spinal cord, to promote a 
feedback inhibition to persistent nociceptive stimuli (Milne et al., 2001; Millan, 2002; 
Hayashida et al., 2008; Chandler and Waterhouse, 2012). This antinociceptive effect 
originates from LC neurons located on the ventral portion in response to incoming pain 
signals from the spinal cord (Millan, 2002; Taylor and Westlund, 2017). LC adrenergic 
neurons, projecting to the dorsal horn of the spinal cord as well as other downstream 
targets, decrease pain facilitation, predominantly through a2 adrenoceptors activation and 
suppression of further ascending signals (Millan, 2002; Gilsbach et al., 2009; Taylor and 
Westlund, 2017). Conversely, LC neurons localized more dorsally project to higher order 
brain regions such as the mPFC and the ACC, inducing effects that vary based on the 
sensory information (Kaushal et al., 2016; Taylor and Westlund, 2017; Wang et al., 
2017). For example, low levels of pain are associated with lower LC activation and 
decreased NE release onto the mPFC, which would predominately activate the higher 
affinity a2-adrenoceptors and decrease pain signaling. Higher levels of LC activation 
would result in more a1-adrenoceptor activity and pain facilitation {Taylor, 2017 #445}. 
In this case, the net response would be the effect of both postsynaptic a1- and a2-
adrenoceptor activation (Taylor and Westlund, 2017). 
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Chronic pain states such as peripheral neuropathy involve a dysregulation of the 
adrenergic system (Martins et al., 2015; Kaushal et al., 2016; Taylor and Westlund, 
2017).  Descending pain circuits from the LC to the spinal dorsal horn that normally 
inhibit nociception through action on predominantly a2-autoreceptors, actually facilitate 
pain through a1-adrenoreceptor (Kaushal et al., 2016; Taylor and Westlund, 2017). In 
addition, the dorsal reticular nucleus (DRt), a downstream target of the LC that normally 
facilitates pain, increases its pronociceptive effect in chronic pain states due to a lack of 
inhibition (Martins et al., 2015). Both of these downstream circuits facilitate pain through 
increased NE binding to the a1 adrenoreceptor; however, there is also a decrease a2 
autoreceptor sensitivity on the LC neuron terminals (Balldin et al., 1992; Martins et al., 
2015; Kaushal et al., 2016). A direct consequence of this impairment is the disinhibition 
of NE release in both regions, allowing for further a1 adrenoceptor binding and pain 
facilitation (Martins et al., 2015; Kaushal et al., 2016). Upstream targets of the LC share a 
similar fate as it was shown that, upon targeted release of NE, the mPFC can shift the 
inhibitory/excitatory balance to a predominately excitatory state (Marzo et al., 2014); In 
particular, it has been hypothesized that, while in resting states the LC-mPFC circuit 
functions mainly via through a2 autoreceptors, during chronic pain instead the increased 
NE release leads to the activation of the low-affinity a1 adrenoceptors and, therefore, 
pain facilitation (Taylor and Westlund, 2017). 
Many of these neuroadaptations to the adrenergic system described for peripheral 
neuropathy parallel those that occur during alcohol withdrawal. The reduced inhibition of 
NMDA receptors during withdrawal causes an increase of NE released from adrenergic 
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neurons originating in the LC (Tsai et al., 1995; Patkar et al., 2003), which in turn leads 
to pain facilitation similar to that observed in chronic pain states (Taylor and Westlund, 
2017). This occurs in concert with a decrease in a2 adrenoceptor sensitivity that has also 
been documented during alcohol withdrawal, which disinhibits NE release and further 
exacerbates pain (Balldin et al., 1992; Martins et al., 2015).  
The present study was conducted in attempt to further the understanding of the 
role of α2 adrenoceptors in alcohol drinking and associated allodynia, to ultimately 
provide a possible promising therapeutic target for AUD. 
 
Study Objective  
The objective of the current study was to investigate the role of the a2 
adrenoceptor in the context of heavy alcohol drinking and associated mechanical 







Subjects of this study were male and female C57B1/6J mice, 7-week old upon 
arrival (Jackson Laboratory). The subjects were single-housed in wire-topped 16.76 cm x 
27.94 cm x 12.32 cm plastic cages. Mice were housed in an AAALAC-approved, 
humidity- (60%) and temperature-controlled (22°C) vivarium on a 12 hr reverse light 
cycle (lights off at 10 AM). Mice were given ad libitum access to food and water unless 
otherwise noted. Experimental protocols were approved by the Boston University 
Medical Campus Institutional Animal Care and Use Committee (IACUC) and adhered to 
the National Institute of Health Guide for the Care and Use of Laboratory Animals as 
well as the Principles of Laboratory Animal Care. 
 
Drugs 
Ethanol solution (20% (v/v)) was prepared using 100% ethanol and with tap 
water. Sucrose solution (1.15% (w/v)) was prepared using sucrose purchased from Sigma 
Aldrich (Natick, MA) and dissolved into tap water. Clonidine (HCl) was purchased from 
Sigma Aldrich (Natick, MA) and dissolved into sterile saline. Clonidine (0-160 µg/kg) 
was injected intraperitoneally (i.p.) in a volume of 10 ml/kg, 30 minutes prior to the start 






Intermittent 2-Bottle Choice Access to Ethanol 
Mice were habituated for 1 week to drink water from two 50-ml Falcon tubes 
(11.5 cm long) equipped with rubber stoppers and metal, double-ball sipper tubes 
purchased from Ancare (Bellmore, NY) (“bottles”). Mice were then given 24 hr access to 
2 bottles, one always containing water, and the other one containing either water (Control 
group in the allodynia experiments) or a 20% (v/v) ethanol solution on alternating days 
(Monday, Wednesday, and Friday) (MWF group), as in {Sabino, 2013 #511}. Fluid 
spillage was recorded from empty cages and it was negligible for both solutions. 
 
The Effect of Clonidine on Ethanol Drinking 
After 20 weeks of access to the intermittent ethanol paradigm, clonidine was 
administered using a within-subject, latin-square design (0-160 µg/kg, i.p.). Food was 
removed during the 30 min pretreatment time and a pre-weighed amount was added to 
the cages along with pre-weighed ethanol and water bottles. Food, alcohol and water 
were measured at the three different time points: 2 hr, 6 hr and 24 hr of access, while 
body weight was measured at time of injection and 24 hr later. Mice were allowed at least 
one treatment-free alcohol drinking session between injection days to ensure return to 
baseline drinking levels. 
 
Effect of Clonidine on Mechanical Allodynia during Withdrawal 
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Mechanical allodynia during withdrawal from alcohol has been well characterized 
(Tiwari et al., 2011). MWF mice were tested after 72 hr withdrawal from ethanol access, 
together with ethanol-naïve mice. An electronic version of the von Frey test known as a 
Dynamic Plantar Anethesiometer was used (Ugo Basile, Varese, Italy),  using a protocol 
adapted from (Carozzi et al., 2013; Campana and Rimondini, 2015). Mice were placed 
into a plexiglass box that was divided into 12 chambers with one mouse in each chamber 
and covered with a plastic top. The box sat upon an elevated mesh grid.  The automatic 
von Frey test uses a metal filament applied vertically to the plantar region of the hind paw 
of the mouse with increasing force until the paw is withdrawn. Prior to testing, the 
automatic von Frey device is calibrated to filament probe by itself to zero the 
measurement, then it was calibrated against the 5 and 50 gram accessory weights because 
our testing force fell between these values.. Mice were tested at three different, 
progressively increasing forces (4 g, 6 g, and 8 g), with a 2 sec ramp up. The force at 
which the paw was withdrawn was recorded for each force applied, and the test was 
repeated at least twice per paw. Withdrawal forces were averaged to determine the mean 
paw withdrawal threshold (PWT) for each animal at each of the forces applied.  
Animals were habituated to the chambers the day before testing for 2 hr and on 
the testing day for 1 hr prior to the test. All animals were first injected with vehicle 
(saline) and tested for baseline mechanical allodynia. Then, clonidine (20 µg/kg, 80 
µg/kg, 160 µg/kg, i.p., each dose tested on a different day) was injected 30 min prior to a 






Sucrose Drinking Paradigm 
 As with the ethanol intake study, a new cohort of ethanol-naive male and female 
mice were first habituated to two water bottles for 1 week. Mice were then given 
intermittent 24 hr access to 2 bottles, one always containing water, and the other one 
containing 1.15 (w/v) sucrose solution on alternating days (Monday, Wednesday, and 
Friday) as in (Hwa et al., 2011; Sabino et al., 2013). Fluid spillage was recorded from 
empty cages and it was found to be negligible for solutions. This sucrose concentration 
was chosen as it results in similar volumes of intake compared to 20% (v/v) ethanol. The 
effect of clonidine (0-160 µg/kg, i.p.) was then assessed on sucrose and water 
consumption at 2 hr, 6 hr and 24 hr, and on food intake at 24 hr. 
 
Statistics 
The effects of clonidine on fluid and food intake in both the ethanol and the 
sucrose experiment were analyzed using three-way repeated measures ANOVAs, with 
dose and time as within-subject factors and sex as a between-subject factor. The effects 
of clonidine on intake at each time point for each sex were then analyzed using one-way 
ANOVAs.  
Data from the mechanical allodynia assessments were analyzed using a three-way 
ANOVA for each of the clonidine doses and for each sex, which were run in separate 
experiments (Dose and Force as within-subjects factors, Group as a between-subject 
factor). The Student Newman-Keuls test was used for pairwise post hoc comparisons; t 
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tests were used when 2 groups were compared. Statistical significance was set at p < 






The Effect of Clonidine on Alcohol Consumption 
 
As shown in Figure 2, the a2 adrenoceptor agonist, clonidine, dose-dependently 
reduced ethanol intake in the MWF mice at the both the 2 hr and 6 hr time points [Dose: 
F(3,45) = 11.87, p < 0.001; Dose x Sex: F(3,45) = 2.11, n.s.; Dose x Time: F(3,45) = 
2.25, n.s.]. In male MWF mice, all doses of clonidine (20 µg/kg, 80 µg/kg, 160 µg/kg) 
decreased ethanol intake at the 2 hr time point.  In female MWF mice treatment with 160 
µg/kg of clonidine, but not 20 µg/kg or 80 µg/kg, decreased ethanol intake at the 2 hr 
time point. In both males and females, the highest dose of clonidine (160 µg/kg) was the 
most effective at suppressing the 20% ethanol intake. At the 6 hr time point, the effect of 
160 µg/kg clonidine on 20% ethanol intake persisted in both males and females. Female 
MWF mice also showed a decrease in consumption of ethanol at 6hr following treatment 
with 80 µg/kg dose of clonidine suggesting a possible delayed effect of the drug. By the 
24 hr time point, the effect of clonidine on 20% ethanol consumption was not present in 
either males or females [Dose: Males: F(3,21) = 0.91, p = n.s.; Females: F(3,24) = 1.85, 
n.s.].  
As shown in Figure 3, clonidine treatment had no effect on water intake at the 2 
hr or 6 hr time point [Dose: F(3,45) = 1.57, n.s.; Dose x Sex: F(3,45) = 0.27, n.s.; Dose x 
Time: F(3,45) = 1.13, n.s.]. An overall effect at the 24 hr time point was observed [Dose: 
F(3,45) = 3.80, p < 0.05; Dose x Sex: F(3,45) = 1.06, n.s.]; however, further post hoc 
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analysis revealed that none of the doses statistically differed as compared to the vehicle 
condition.  
At the 2 hr and 6 hr time points (Figure 4), clonidine administration significantly 
affected total fluid intake [Dose: F(3,45) = 4.61, p < 0.01; Dose x Sex: F(3,45) = 1.79, 
n.s.; Dose x Time: F(3,45) = 2.83, p < 0.05]. In both males and females, the 160 µg/kg 
clonidine treatment decreased total fluid intake at the 2 hr time point. At the 6 hr time 
point, the effect of clonidine on total fluid intake persisted in females, but not in males. 
Furthermore, both 80 µg/kg and 160 µg/kg clonidine treatments significantly decreased 
the total fluid intake at the 6 hr time point in females. Since clonidine had no effect on 
water intake, this decrease in total fluid intake is likely to result from the effects of drug 
treatment on ethanol consumption. Clonidine continued to have an effect on total fluid 
intake at the 24 hr time point [Dose: F(3,45) = 2.94, p < 0.05; Dose x Sex: F(3,45) = 0.99, 
n.s.]. However, post hoc comparisons revealed no differences in total fluid intake among 
groups.  
As shown in Figure 5, clonidine administration significantly affected ethanol 
preference at the 2 hr and 6 hr time points [Dose: F(3,51) = 6.26, p < 0.01; Dose x Sex: 
F(3,51) = 0.82, n.s.; Dose x Time: F(3,51) = 1.27, n.s.]. Specifically, the 160 µg/kg dose 
of clonidine reduced ethanol preference in males, but not females, at the 2 hr time point. 
At the 6 hr time point, the same 160 µg/kg treatment decreased ethanol preference in 
females, but not in males. This effect of clonidine on alcohol preference was still 
observed at the 24 hr time point [Dose: F(3,51) = 3.79, p < 0.05; Dose x Sex: F(3,51) = 
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1.52, n.s.], even though only females exhibited a significant decrease in ethanol 
preference. 
As shown in Figure 6, clonidine administration significantly affected food intake 
at the 2 hr and 6 hr time points [Dose: F(3,45) = 2.89, p < 0.05; Dose x Sex: F(3,45) = 
0.34, n.s.; Dose x Time: F(3,45) = 0.46, n.s.]. However, further post-hoc analysis showed 
no differences among groups at any time point in either sex. At the 24 hr time point, 
clonidine administration had no effect of on food intake [F(3,45) = 0.27, n.s.; Dose x Sex: 






Figure 2: Effect of clonidine on ethanol intake.  
Effect of acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist clonidine 
on 20% v/v ethanol intake at 2 hr, 6 hr (A, C) and 24 hr (B, D), in males (A, B) and females (C, 
D); (N = 8-9/group). Data represent mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle-





Figure 3: Effect of clonidine on water intake.  
Effect of acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist clonidine 
on water intake at 2 hr and 6 hr (A, C) and 24 hr (B, D), in males (A. B) and females (C, D). (N = 





Figure 4: Effect of clonidine on total fluid intake.  
Effect of acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist clonidine 
on total fluid intake at 2 hr and 6 hr (A, C) and 24 hr (B, D), in males (A, B) and females (C, D) 






Figure 5: Effect of clonidine on ethanol preference.  
Effect of acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist clonidine 
on the preference of 20% v/v ethanol solution over water at 2 hr and 6 hr (A, C) and 24 hr (B, D), 
in males (A, B) and females (C, D) (N = 8-9/group). Data represent mean ± SEM. * p<0.05 vs. 





Figure 6: Effect of clonidine on food intake.  
Effect of acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist clonidine 
on food intake at 2 hr, 6 hr (A, C) and 24 hr (B, D), in males (A, B) and females (C, D) (N = 8-






The Effect of Clonidine on Mechanical Allodynia During 72 hr Alcohol Withdrawal  
After a 72 hr cessation from intermittent two-bottle choice alcohol consumption, 
vehicle-treated male and female MWF mice exhibited a lower pain threshold compared to 
controls [20 µg/kg, Group: Males: F(1,10) =, p < 0.001; Females: F(1,10) =, p < 0.001; 
80 µg/kg, Group:: Males: F(1,10) =, p < 0 .001; Females: F(1,10) =, p < 0.001; 160 
µg/kg, Group: Male: F(1,10) =, p < 0.01; Female: F(1,10) =, p < 0.001]. Specifically, 
both male and female MWF mice treated with saline had lower pain thresholds on each 
of the three testing days at both 6 and 8 g of applied force, as shown in Figures 7 and 8. 
The administration of clonidine decreased pain sensitivity (i.e. increased paw 
withdrawal threshold in MWF mice of both sexes [20 µg/kg, Treatment x Group: Males: 
F(1,10) = 89.14, p < 0.001; Females: F(1,10) = 29.12, p < 0.001; 80 µg/kg, Treatment x 
Group: Males: F(1,10) = 102.26, p < 0.001; Females: F(1,10) = 27.70, p < 0.001; 160 
µg/kg, Treatment x Group: Male: F(1,10) = 14.73, p < 0.01; Female: F(1,10) = 60.10, p < 
0.001]. Specifically, in male MWF mice, treatment with all 3 doses of clonidine reversed 
the increased pain sensitivity observed during withdrawal at all applied force intensities 
(no difference from control mice treated with saline). In MWF female mice, all 3 doses of 
clonidine treatment reversed the pain sensitivity when tested with 4 and 6 g of applied 
force, but only the highest dose reversed it at 8 g of applied force (no difference from 
control mice treated with saline). 
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Figure 7: Effect of clonidine on mechanical allodynia in MWF and control male mice.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor antagonist 
clonidine (0-160 µg/kg) on paw withdrawal threshold force in 72 hr ethanol-withdrawn MWF and 
in control male mice (N = 6/group). Data represent mean ± SEM. * p<0.05; ** p<0.01; *** 





Figure 8: Effect of clonidine on mechanical allodynia in MWF and Control female mice. 
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor antagonist 
clonidine (0-160 µg/kg) on paw withdrawal threshold force in 72 hr ethanol-withdrawn MWF and 
in control female mice (N = 6/group). Data represent mean ± SEM. * p<0.05; ** p<0.01; *** 




The Effect of Clonidine on Sucrose Consumption 
As shown in Figure 9, clonidine did not significantly affect sucrose intake at 
either the 2 hr and 6 hr time points [Dose: F(3,51) = 0.55, n.s.; Dose x Sex: F(3,51) = 
1.06, n.s.; Dose x Time: F(3,51) = 0.79, n.s.], or at the 24 hr time point [Dose: F(3,51) = 
1.45, n.s.; Dose x Sex: F(3,51) = 0.38, n.s.]. 
As shown in Figure 10, clonidine had no significant effects on water intake at 
either the 2 hr and 6 hr time points [Dose: F(3,51) = 0.53, n.s.; Dose x Sex: F(3,51) = 
1.03, n.s.; Dose x Time: F(3,51) = 0.76, n.s.], or at the 24 hr time point [Dose: F(3,51) = 
0.50, n.s.; Dose x Sex: F(3,51) = 0.91, n.s.] 
As shown in Figure 11, clonidine had no significant effect on total fluid intake at 
either the 2 hr and 6 hr time points [Dose: F(3,51) = 0.74, n.s.; Dose x Sex: F(3,51) = 
1.30, n.s.; Dose x Time: F(3,51) = 0.67, n.s.], or at the 24 hr time point [Dose: F(3,51) = 
1.35, n.s.; Dose x Sex: F(3,51) = 0.51, n.s.] 
Figure 12 shows that the administration of clonidine also did not change the 
preference for sucrose [2 hr and 6 hr: Dose: F(3,51) = 2.30, n.s.; Dose x Sex: F(3,51) = 
1.02, n.s.; Dose x Time: F(3,51) = 2.72, n.s.; 24 hr: Dose: F(3,51) = 1.09, n.s.; Dose x 
Sex: F(3,51) = 0.70, n.s.].  
As shown in Figure 13, there was a main effect of clonidine treatment on food 
intake [Dose: F(3,51) = 7.22, p < 0.001; Dose x Sex: F(3,51) = 0.78, n.s.; Dose x Time: 
F(3,51) = 0.20, n.s.]. Post hoc analysis revealed a significant decrease in food 
consumption at the 6 hr time point in both males and females only following the highest 
dose (160 µg/kg) of clonidine. The effect of clonidine on food intake was not present 
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Figure 9: Effect of clonidine on sucrose intake.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2 adrenoceptor agonist 
clonidine (0-160 µg/kg) on intake of 1.15% w/v sucrose solution at 2 hr and 6 hr (A, C) and 24 hr 





Figure 10: Effect of clonidine on water intake.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2-adrenoceptor agonist 
clonidine (0-160 µg/kg) on intake of water at 2 hr and 6 hr (A, C) and 24 hr (B, D), in males (A, 




Figure 11: Effect of clonidine on total fluid intake in MWF mice.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2-adrenoceptor agonist 
clonidine (0-160 µg/kg) on intake of total fluid at 2 hr and 6 hr (A, C) and 24 hr (B, D), in males 





Figure 12: Effect of clonidine on sucrose preference.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2-adrenoceptor agonist 
clonidine (0-160 µg/kg) on the preference of 1.15% w/v sucrose solution over water at 2 hr and 6 





Figure 13: Effect of clonidine on total fluid intake in MWF mice.  
Effect of an acute i.p. pretreatment (– 30 min) with the selective a2-adrenoceptor agonist 
clonidine (0-160 µg/kg) on intake of total fluid at 2 hr and 6 hr (A, C) and 24 hr (B, D), in males 






These experiments provide evidence that a2 adrenergic receptor agonism via 
systemic clonidine injection: i) decreased ethanol consumption; ii) had no effect of the 
consumption of naturally-reinforcing substances such as sucrose; iii) decreased 
mechanical allodynia during abstinence from alcohol. 
 
Effect of Clonidine on Ethanol Consumption 
 a2-agonists, such as clonidine, have been recognized in their potential utility to 
decrease ethanol consumption in home cage drinking and self-administration models in 
both rats and mice (Opitz, 1990; Le et al., 2005; Rasmussen et al., 2014). Our results 
support these claims, and bring them a step further showing the effect of clonidine on 
ethanol consumption persisted for 6 hours post injection as opposed to only 2 hours found 
in other studies.  Alongside the decreased ethanol intake seen, clonidine had no effect on 
water or food intake, suggesting decreased ethanol intake was not due to nonspecific 
effects on homeostatic mechanisms. Unaltered consummatory behavior also indicates that 
even the highest doses of clonidine used did not sedate mice to the point of affecting the 
intake of food or water which has been previously observed (Opitz, 1990).. 
 As mentioned previously, the noradrenergic system has been linked to the 
changes in behavior associated with ethanol drinking as well as a variety of other drugs 
of abuse (Maldonado, 1997; Fitzgerald, 2013; Rasmussen et al., 2014; McKee et al., 
2015). A previous study indicated that the inhibition of dopaminergic (DA) neurons in 
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the ventral tegmental area (VTA) decreases  voluntary ethanol consumption (Carnicella 
et al., 2009).These dopaminergic neurons are modulated by excitatory glutamatergic 
transmission which is, in turn, inhibited by the activation of a2-adrenoreceptors (Jimenez-
Rivera et al., 2012). Thus, clonidine’s ability to reduce ethanol intake may be through 
reduction of VTA dopaminergic activity..  
Presynaptic a2-adrenoceptors have also been found on glutamatergic neurons 
within NAc, another critical reward center of the brain (Peng et al., 2018).  Importantly, 
the pharmacological blockade of metabotropic glutamate receptors decreases voluntary 
ethanol consumption in animals (Cozzoli et al., 2009; Cozzoli et al., 2012; Lum et al., 
2014). Since the administration of clonidine on excitatory glutamatergic neurons results 
in a decrease in glutamate release onto the NAc (Peng et al., 2018), it is possible that a 
reduction of glutamatergic receptor activation could be responsible for the decrease in 
voluntary ethanol consumption seen in our studies.  
Alternatively, reductions in drinking behavior following clonidine administration 
could be the result of reversing the allodynia associated with alcohol withdrawal. People 
have an increased tendency to use alcohol when in chronic pain states (Riley and King, 
2009), and chronic alcohol use can result in the development of pain (Apkarian et al., 
2013). This pain is also exacerbated during withdrawal states (Dina et al., 2006; Apkarian 
et al., 2013), which may increase the propensity of an individual to drink alcohol to 
ameliorate these negative feelings (Egli et al., 2012). However, we have not tested 
changes in pain sensitivity or mechanical allodynia during acute alcohol withdrawal, nor 
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have we studied ethanol drinking following prolonged withdrawal. Future studies testing 
these variables must be done to support this hypothesis.  
 
Effect of Clonidine on Sucrose Consumption 
 Despite the decrease in ethanol consumption following clonidine administration, 
a2-agonism did not affect consumption or preference of the sucrose solution. These 
results are suggestive that the effect of clonidine on ethanol consumption is selective to 
alcohol, and not simply a generalized suppression of the intake of reinforcing substances 
as demonstrated previously (Rasmussen et al., 2014). In a 2014 study, the administration 
of an 80 µg/kg dose of clonidine decreased saccharin consumption in alcohol preferring 
rats (Rasmussen et al., 2014). However, those results do not necessarily pertain to results 
of the current study, since the notable decrease in saccharin consumption may have been 
due to the animals being genetically predisposed to drinking resulting in extraneous 
effects on the consumption of a palatable substance. It has also been hypothesized that 
the lack of ethanol drinking following high doses of clonidine may have been the result 
of a hypontic effect (Bender and Abdel-Rahman, 2009; Rasmussen et al., 2014). This 
effect could have been the reason that there was a decrease in food consumption during 
the experiment, however, this was not evident in either the water or sucrose intake and 
only occurred at the highest clonidine dose used in this study (160 µg/kg). There was also 
no change in food consumption in mice during the tests with the same dose during 
ethanol consumption, which could be due to some effect of ethanol conusmption 
promoting eating behavior. With this being said, it is unlikely that the reductions of 
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ethanol intake (especially at the lower clonidine doses) can be attributed to clonidine-
induced sedation.  
 
Effect of Clonidine on Withdrawal-Induced Mechanical Allodynia 
 Our current data demonstrates that 72hr abstinence from chronic intermittent 
alcohol access produces mechanical allodynia in ethanol drinking mice. Mechanical 
allodynia is a symptom that can develop due to a variety of pathological and 
environmental factors such as diabetes, cancer, peripheral or central nerve damage, and 
AUD (Yaksh et al., 1995; Dina et al., 2006; Yeo et al., 2016; Chen et al., 2017). In the 
case of AUD, the severity of allodynia has been shown to increase during periods of 
withdrawal through mechanisms that are not fully understood (Dina et al., 2006; 
Apkarian et al., 2013). Due to the efficacy of a2-agonists in treating various symptoms of 
alcohol withdrawal (Bjorkqvist, 1975; Linnoila et al., 1987; Muzyk et al., 2011), 
clonidine was deemed a suitable drug to test in the treatment of alcohol withdrawal-
induced mechanical allodynia.  
In order to produce withdrawal states, mice were subjected to a chronic 
intermittent (MWF) 24hr 20% v/v ethanol access schedule which has been documented to 
produce significantly higher levels of ethanol consumption compared to continuous (7 
days/week) ethanol access procedures (Sabino et al., 2013; Carnicella et al., 2014). In 
contrast to other studies testing nociceptive thresholds (Yaksh et al., 1995; Dina et al., 
2006; Geng et al., 2016), this experiment utilized the electronic von Frey apparatus 
allowing for a more accurate resolution of withdrawal threshold than the manual method 
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(Martinov et al., 2013). The mice were tested after a 72 hr cessation from alcohol, as this 
period of withdrawal has been known to produce maximum pain sensitivity (Dina et al., 
2006). The presence of alcohol withdrawal was demonstrated during baseline testing with 
MWF mice exhibiting a reduced pain threshold relative to controls. These results were 
consistent with those signifying an increase in pain sensitivity during alcohol withdrawal 
in humans (Jochum et al., 2010) and rodents (Dina et al., 2006; Alongkronrusmee et al., 
2016). We also found that, in most cases, there was no pain response following 4 grams 
of applied force. We determined that this force was subthreshold even during mechanical 
allodynia.  However, following vehicle treatment during the 80 µg/kg mechanical 
sensitivity test, female MWF mice had a lower pain threshold at the 4 gram weight 
compared to control animals which was not evident during any other test. This increased 
pain sensitivity could be due to a lack of endogenous analgesic action during times of 
stress which has been characterized in female, compared to male, mice (Wiesenfeld-
Hallin, 2005). 
The direct cause of alcohol-induced allodynia is still unclear, but it seems to 
involve a combination of both central and peripheral factors (Jochum et al., 2010; 
Mellion et al., 2011; Apkarian et al., 2013). The peripheral mechanisms involve damage 
to peripheral nerve fibers by alcohol neurotoxicity in combination with thiamine 
deficiencies that are common in patients with AUD (Mellion et al., 2011). However, this 
hypothesis does not explain the increases of pain sensitivity during periods of prolonged 
alcohol abstinence. Central mechanisms of alcohol-induced allodynia suggest a 
dysregulation in neural pathways that result in an imbalance of nociceptive signaling and 
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altered pain states (Jochum et al., 2010; Egli et al., 2012; Apkarian et al., 2013). In this 
case, alcohol withdrawal would add to the neural imbalance through increases in stress 
factors and sympathetic hyperactivity leading to further increases in pain sensitization 
(Egli et al., 2012; Apkarian et al., 2013). Due to its role in pain modulation, the 
adrenergic system has been linked to chronic pain states following chronic alcohol 
consumption (Ferrari et al., 2013). There has been no direct connection between the a2-
adrenergic receptor and its role in the expression of alcohol-induced allodynia until the 
present study. It has been shown that the decreased sensitivity of a2-adrenoceptors due to 
chronic ethanol consumption leads to a subsequent lack of inhibition of NE release within 
the brain, and we can speculate that would lead to further NE release onto pronociceptive 
brain and spinal areas (Balldin et al., 1992; De Witte et al., 2003; Taylor and Westlund, 
2017). The increased NE release following sympathetic hyperactivity would also lead to 
increased a1-adrenoceptor binding, facilitating pain production (Meisner et al., 2007; 
Martins et al., 2015; Kaushal et al., 2016). However, further studies are needed to 
determine the extent that a2-adrenoceptor modulation leads to alcohol-induced allodynia. 
The results of the current study demonstrated that clonidine reversed the 
mechanical allodynia induced by 72hr alcohol withdrawal. Though this is the first study 
to examine the effects of clonidine on the treatment of alcohol-induced allodynia, 
previous studies using a chronic constriction and diabetic model for pain found 
reductions in allodynia following treatment with an a2-agonist  (Alba-Delgado et al., 
2012; Chen et al., 2017; Wang et al., 2017). It has been suggested that the antinociceptive 
effects of clonidine are localized to sensory neurons of the dorsal horn of the spinal cord 
 
41 
(Yaksh et al., 1995; Zeitz et al., 2001). The increase of allodynia in chronic pain states is 
correlated with a decrease in a2-adrenoceptor sensitivity and expression within the dorsal 
horn and an increase of NE turnover by adrenergic neurons (Leiphart et al., 2003; Chen et 
al., 2017). Intrathecal administration of an a2-agonist potently activates these remaining 
receptors, attenuating the allodynia and causing an antinociceptive effect (Yaksh et al., 
1995; Zeitz et al., 2001). As mentioned previously, there is a notable decrease in a2-
adrenoreceptor sensitivity during alcohol withdrawal that might be why potent agonism is 
required to reverse the allodynia found in the mice (Balldin et al., 1992); however, the 
extent of this effect in the spinal cord has yet to be determined. Intrathecal administration 
of clonidine also shows a reduction of effectiveness as a treatment over time (Llorca-
Torralba et al., 2016). This is likely due to the fact that the population of a2-
adrenoceptors in the spinal cord are both postsynaptic and presynaptic (Taylor and 
Westlund, 2017). The postsynaptic receptors mediate the descending antinociception, but 
activation of the presynaptic autoreceptors inhibit NE transmission the postsynaptic 
receptors (Wei and Pertovaara, 2006). This suggests that the inhibition of allodynia by 
clonidine is not solely mediated by spinal a2-adrenoceptor activation, and some of the 
action of clonidine in this experiment is likely due the modulation of brain areas. Further 
studies using a2-antagonists in conjunction with systemic treatment with an a2-agonist 
may be able to determine the extent to which each of these systems contribute to 
antinociception.  
There is evidence that a2-agonism of certain brain regions exerts an 
antinociceptive effect in neuropathic pain models. The ACC is one such region which has 
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been previously documented in its role in regulating acute and chronic pain (Bliss et al., 
2016). Optogenetic experiments that activated excitatory neurons in the ACC decreased 
the mechanical threshold of mice (Kang et al., 2015), while topical application of 
clonidine to the ACC decreases mechanical allodynia in chronic constriction models 
(Wang et al., 2017). It was also found that during periods of alcohol withdrawal, there is 
an increase of activity in the ACC (Smith et al., 2017) which could lead to allodynia in 
mice.  
Inhibition of the DRt via clonidine could be another mechanism that reverses 
mechanical allodynia. The DRt provides a descending excitatory pathway to the spinal 
cord which enhances pain facilitation in response to incoming nociceptive signals (Lima 
and Almeida, 2002). It also receives a majority of its upstream input from brainstem 
noradrenergic nuclei such as the LC and A5 (Almeida et al., 2002) which increases 
activity and facilitates neuropathic pain through a1-activation (Martins et al., 2010; 
Martins et al., 2015). Microinjection of clonidine into the DRt resulted in an inhibition of 
pain sensitivity in nerve injury models, however, the response was significantly smaller 
in injured mice than controls (Martins et al., 2015). This suggests that there is a decreased 
a2-adrenoceptor sensitivity in the DRt in neuropathic pain (Martins et al., 2015). The 
present study showed that there was no difference in the antinociceptive effect of 
clonidine in MWF mice compared to controls. This could suggest that the reduction of 
a2-adrenoceptor sensitivity was not as significant during alcohol withdrawal as it was 
following nerve injury. However, further studies must be conducted to determine the 
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extent of a2-adrenoceptor modulation during alcohol withdrawal in pain facilitating areas 
such as the DRt.  
 
Conclusion 
Very little is known about the effect of a2-agonists in alcohol-induced allodynia. 
Given that ethanol withdrawal has been related to dysregulation of the adrenergic system 
which plays a large role in pain regulation, it is not surprising that withdrawal induces 
chronic pain states. The current study demonstrates that administration of clonidine 
reverses the withdrawal-induced allodynia, as well as reduces excessive drinking in mice. 
Though the exact mechanism producing this result is unclear, the behavioral effects are 
apparent. Further studies should be focused on the neurochemical changes that occur 
within the brain during withdrawal-induced allodynia in order to determine effective 
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